Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-α, releasing matrix metalloproteinase-9 and migrating in vitro by Takata, Fuyuko et al.
RESEARCH Open Access
Brain pericytes among cells constituting the
blood-brain barrier are highly sensitive to tumor
necrosis factor-a, releasing matrix
metalloproteinase-9 and migrating in vitro
Fuyuko Takata
1,2, Shinya Dohgu
1,3, Junichi Matsumoto
1, Hiroyuki Takahashi
1, Takashi Machida
1, Tomoya Wakigawa
1,
Eriko Harada
1, Haruki Miyaji
1, Mitsuhisa Koga
1, Tsuyoshi Nishioku
1, Atsushi Yamauchi
1,3 and Yasufumi Kataoka
1,2*
Abstract
Background: Increased matrix metalloproteinase (MMP)-9 in the plasma and brain is associated with blood-brain
barrier (BBB) disruption through proteolytic activity in neuroinflammatory diseases. MMP-9 is present in the brain
microvasculature and its vicinity, where brain microvascular endothelial cells (BMECs), pericytes and astrocytes
constitute the BBB. Little is known about the cellular source and role of MMP-9 at the BBB. Here, we examined the
ability of pericytes to release MMP-9 and migrate in response to inflammatory mediators in comparison with
BMECs and astrocytes, using primary cultures isolated from rat brains.
Methods: The culture supernatants were collected from primary cultures of rat brain endothelial cells, pericytes, or
astrocytes. MMP-9 activities and levels in the supernatants were measured by gelatin zymography and western
blot, respectively. The involvement of signaling molecules including mitogen-activated protein kinases (MAPKs) and
phosphoinositide-3-kinase (PI3K)/Akt in the mediation of tumor necrosis factor (TNF)-a-induced MMP-9 release was
examined using specific inhibitors. The functional activity of MMP-9 was evaluated by a cell migration assay.
Results: Zymographic and western blot analyses demonstrated that TNF-a stimulated pericytes to release MMP-9,
and this release was much higher than from BMECs or astrocytes. Other inflammatory mediators [interleukin (IL)-1b,
interferon-g, IL-6 and lipopolysaccharide] failed to induce MMP-9 release from pericytes. TNF-a-induced MMP-9
release from pericytes was found to be mediated by MAPKs and PI3K. Scratch wound healing assay showed that in
contrast to BMECs and astrocytes the extent of pericyte migration was significantly increased by TNF-a. This
pericyte migration was inhibited by anti-MMP-9 antibody.
Conclusion: These findings suggest that pericytes are most sensitive to TNF-a in terms of MMP-9 release, and are
the major source of MMP-9 at the BBB. This pericyte-derived MMP-9 initiated cellular migration of pericytes, which
might be involved in pericyte loss in the damaged BBB.
Background
Brain pericytes are located adjacent to capillaries and share
a common basement membrane with brain microvascular
endothelial cells (BMECs). This allows pericytes to com-
municate directly with BMECs through gap junctions and
peg-and-socket contacts to stabilize microvessels and
regulate cerebral blood flow by their contractile and relax-
ant properties [1-3]. Along with BMECs and astrocytes,
pericytes constitute the blood-brain barrier (BBB), and
communicate with BMECs through release of soluble fac-
tors, leading to the up-regulation of BBB functions [4-8].
Recently, it has been reported that BBB breakdown and
hypoperfusion occurs in viable pericyte-deficient mice
[9,10], suggesting that brain pericytes play a crucial role in
BBB integrity and cerebral microcirculation under healthy
conditions. Furthermore, the genetic animal models of
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integrity is determined by the extent of pericyte coverage
of cerebral microvessels [9]. Thus, BBB dysfunction is
attributed to brain pericyte loss in the microvasculature.
Pericyte loss or reduced pericyte coverage has been
observed in several pathological animal models. We
demonstrated that detachment of brain pericytes from
the basal lamina occurs in disruption of the BBB, caused
by lipopolysaccharide (LPS)-induced sepsis in mice [11].
In cerebral ischemia, which induces BBB disruption
[12], the detachment and migration of brain pericytes
were observed [13]. These findings suggest that these
pericyte behaviors are involved in BBB disruption. It has
been reported that brain pericytes extend toward the
parenchyma, and the basal lamina becomes thin in the
early stage of brain hypoxia [14] and traumatic injury
[15]. These morphological alterations were interpreted
as the initial step of pericyte migration [16]. In this step,
pericytes appear to exhibit high proteolytic activities.
Matrix metalloproteinases (MMPs), a family of zinc-
dependent endopeptidases, are expressed in pericytes to
degrade the components of the extracellular matrix
under physiological conditions. Elevated levels of MMP-9
in brain with cerebral ischemia [17,18] are closely asso-
ciated with BBB disruption [19,20]. In BMECs, astrocytes,
microglia and neurons, MMP-9 production is stimulated
by proinflammatory cytokines including tumor necrosis
factor (TNF)-a.T N F - a, a known mediator of neuroin-
flammation, is produced by brain insults such as stroke.
BBB permeability and MMP-9 expression in the brain
microvessels were increased in obese mice with stroke
[21]. These findings raise the possibility that brain micro-
vessels rather than brain parenchyma are the major
source of MMP-9.
To test whether MMP-9 production and subsequent
migration of pericytes contribute to BBB disruption asso-
ciated with neuroinflammation, we examined the ability
of pericytes to release MMP-9 and migrate in response to
TNF-a, and compared it with that of BMECs and
astrocytes.
Methods
Materials
Dulbecco’s modified Eagle’sm e d i u m( D M E M )a n d
DMEM/Ham’s nutrient mixture F-12 medium (DMEM/
F12) were purchased from Wako (Osaka, Japan) and
S i g m a( S t .L o u i s ,M O ,U S A ) ,r espectively. Fetal bovine
serum (FBS) and plasma-derived serum (PDS) were pur-
chased from Biowest (Nuaillé, France) and Animal Tech-
nologies Inc. (Tyler, TX, USA), respectively. TNF-a was
from R&D systems Inc. (Minneapolis, MN, USA). U0126,
SP600125, SB203580 and LY294002 were from Tocris
(Ellisville, MO, USA).
Cell culture
All procedures involving experimental animals were
conducted in accordance with the law (No. 105) and
notification (No.6) of the Japanese Government, and
were approved by the Laboratory Animal Care and Use
Committee of Fukuoka University.
Primary cultures of rat brain pericytes and rat brain
microvascular endothelial cells (RBECs) were prepared
from three-week-old Wistar rats, as previously described
[1,4,22,23]. The meninges were carefully removed from
forebrains, and the gray matter was minced in ice-cold
DMEM and digested with collagenase type 2 (1 mg/mL,
Worthington, Lakewood, NJ, USA) for 1.5 h at 37°C. The
pellet was separated by centrifugation in 20% bovine serum
albumin (BSA)-DMEM (1000 × g, 20 min). The microves-
sels obtained in the pellet were further digested with col-
lagenase/dispase (1 mg/mL, Roche, Mannheim, Germany)
for 1 h at 37°C. Microvessel clusters containing pericytes
and endothelial cells were separated on a 33% continuous
Percoll (GE Healthcare, Buckinghamshire, UK) gradient,
collected and washed twice with DMEM before plating on
non-coated dishes and collagen type IV-fibronectin (both
0.1 mg/mL) coated dishes. Brain pericyte cultures were
maintained in DMEM supplemented with 20% FBS and
50 μg/mL gentamicin (Biowest). After seven days in cul-
ture, pericytes at 80-90% confluency were used for experi-
ments. RBEC cultures were maintained in RBEC medium Ι
[DMEM/F12 supplemented with 10% PDS, basic fibroblast
growth factor (1.5 ng/mL, Roche), heparin (100 μg/mL,
Sigma), insulin (5 μg/mL), transferrin (5 μg/mL), sodium
selenite (5 ng/mL; insulin-transferrin-sodium selenite
media supplement, Sigma) and gentamicin (50 μg/mL)]
containing puromycin (4 μg/mL, Sigma) at 37°C in a humi-
dified atmosphere of 5% CO2/95% air, for two days. To
remove the puromycin, cells were washed three times with
fresh RBEC medium Ι and incubated with this medium on
the third day. On the fifth day, RBECs typically reached
80-90% confluency.
Primary astrocyte cultures were prepared from the cere-
bral cortex of one- to three-day-old Wistar rats according
to the method of McCarthy and de Vellis (1980) [24] with
a slight modification. Briefly, after removing the meninges
and blood vessels, the forebrains were minced and gently
dissociated by repeated pipetting in DMEM containing
10% FBS, 100 units/mL penicillin (Nacalai Tesque, Kyoto,
Japan) and 100 μg/mL streptomycin (Nacalai Tesque), and
filtered through a 70-μm cell strainer. Cells were collected
by centrifugation (800 × g, 6 min), resuspended in 10%
FBS DMEM and cultured in 75-cm
2 flasks (BD Bios-
ciences, Franklin Lakes, NJ, USA) in a humidified atmo-
sphere of 5% CO2/95% air at 37°C. Cells were fed every
2-3 days by changing medium. After 10-14 days in culture,
floating cells and weakly attached cells of the mixed
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shaking of the flask. Then, astrocytes at the bottom of the
culture flask were trypsinized and seeded into new culture
flasks. The primary cultured astrocytes were maintained in
10% FBS/DMEM. They were grown in a humidified atmo-
sphere of 5% CO2/95% air at 37°C. Cells at the second or
third passage were used for experiments.
Western blot analysis
Brain pericytes, astrocytes and RBECs were incubated
with or without different concentrations of TNF-a at
37°C for the indicated time. When protein kinase inhibi-
tors were used, they were added 15 min prior to the
application of TNF-a. To compare the expression of
TNF-a receptor 1 (TNFR1) and TNF-a receptor 2
(TNFR2) among brain pericytes, astrocytes and RBECs,
these cells were used without TNF-a treatment. The
culture supernatants were collected and concentrated
~60-fold using Amicon
® Ultra centrifugal filter devices
(cut-off MW: 30 kDa, Millipore Corporation, Billerica,
MA, USA). Cells were scraped and lysed in phosphopro-
tein lysis buffer (10 mM Tris-HCl, pH 6.8, 100 mM
NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 0.1%
SDS, 0.5% sodium deoxycholate, 2 mM Na3VO4,5 0m M
NaF, 20 mM sodium pyrophosphate decahydrate and
50 μg/mL phenylmethylsulfonyl fluoride) containing 1%
phosphatase inhibitor cocktail 1 (Sigma), 1% phosphatase
inhibitor cocktail 2 (Sigma) and 1% protease inhibitor
cocktail (Sigma). The total protein concentration in cell
lysates was determined using a BCA Protein assay kit
(Pierce, Rockford, IL, USA). Equivalent amounts of pro-
tein from each sample were electrophoretically separated
on 5-20% SDS-polyacrylamide gels (Bio Craft Co., Ltd.,
Tokyo, Japan), and then transferred to polyvinylidene
difluoride membranes (Bio-Rad Laboratories, Hercules,
CA, USA). Membranes were blocked with Blocking One
(Nacalai Tesque) or Blocking One-P (Nacalai Tesque) for
phosphorylated proteins. Phosphorylation of p42/p44
mitogen-activated protein kinase (MAPK), p38 MAPK, c-
Jun N-terminal kinase (JNK) and Akt were detected with
primary antibodies against phospho-p42/p44 MAPK
(1:2000; Cell Signaling Technology, Danvers, MA, USA),
phospho-p38 MAPK, phospho-JNK and phospho-Akt
(1:1000; Cell Signaling Technology). MMP-9 and MMP-2
in culture supernatant were detected using antibodies
against MMP-9 (1:500; Millipore Corporate) and MMP-2
(1:500; R&D Systems Inc.). TNFR1 and TNFR2 in cell
lysates were detected with an anti-MMP-9 antibody
(1:200; Santa Cruz Biotechnology Inc., Delaware, CA,
USA) and anti-MMP-2 antibody (1:1000; Cell Signaling
Technology). After washing, membranes were incubated
with an appropriate horseradish peroxidase-conjugated
secondary antibody. To reprobe total p42/p44 MAPK,
p38 MAPK, JNK and Akt, membranes were incubated in
stripping buffer (0.2 M glycine, 0.1% SDS and 1% Tween
20, pH 2.2) for 15 min twice. Total p42/p44 MAPK, p38
MAPK, JNK and Akt were detected using primary anti-
bodies against p42/p44 MAPK, p38 MAPK, JNK and Akt
(1:1000; Cell Signaling Technology). The immunoreactive
bands were visualized using an ECL Advance Western
Blotting Detection Kit (GE Healthcare). The band images
were digitally captured with a FluorChem SP imaging
system (Alpha Innotech, San Leandro, CA, USA) and
band intensities were quantified using AlphaEaseFC soft-
ware (Alpha Innotech). The relative intensity of phos-
phorylation of individual proteins was expressed as the
ratio of phosphorylated protein and the corresponding
total protein.
Gelatin zymography
Brain pericyte-conditioned media were concentrated by
Amicon
® Ultra centrifugal filter devices, and then sub-
jected to zymography according to the manufacturer’s
recommendations (Life laboratory company, Yamagata,
Japan). Zymographic results were expressed as MMP
proteolytic activity and were measured with a FluorChem
SP imaging system and band intensities were quantified
using AlphaEaseFC software.
Migration assay
Rat brain pericytes, RBECs and astrocytes were seeded on
collagen IV-coated center-well organ culture dishes (BD
Biosciences) and cultured to confluence in 20% FBS/
DMEM, RBEC medium I and 10% FBS/DMEM, respec-
tively. Cells were scratched manually with a sterile 0.1-10
μL pipette tip, and the detached cells were removed by
washing three times with serum-free DMEM or serum-free
RBEC medium I. To test whether MMP-9 participates in
TNF-a-induced migration of pericytes, the cells were
exposed to control mouse IgG (10 μg/mL; Sigma) with 10%
FBS/DMEM (vehicle) and mouse monoclonal anti-MMP-9
antibody (1:20; clone 2C3, Abcam, Cambridge, MA, USA)
or control mouse IgG (10 μg/mL) with TNF-a (50 ng/mL).
Astrocytes and RBECs were exposed to 10% FBS/DMEM
and RBEC medium I with or without TNF-a (50 ng/mL),
respectively. Then, cells were incubated for 72 h. Phase
contrast images of seven to eight fixed positions in the
wound area were taken at 0 and 72 h after scratching using
a microscope with a built-in digital camera (Biozero, BZ-
8000; KEYENCE, Osaka, Japan). In the images, the edge of
the initial wound area was marked by lines using BZ-Analy-
zer software (KEYENCE) just before scratching. The edge
of the initial wound area was overlaid with the image taken
at 72 h after scratching. The number of cells migrating into
the initial wound area was counted at 72 h after scratching.
T h ed a t aw e r eo b t a i n e df r o mt h r e es e p a r a t ea s s a y s .
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Results are shown as means ± S.E.M. The statistical sig-
nificance of differences between groups was assessed by
one-way analysis of variance (ANOVA) for factorial com-
parisons and by Dunnett’s or Tukey-Kramer’st e s tf o r
multiple comparisons. Differences were considered sig-
nificant when P values were less than 0.05, using Graph-
Pad Prism 5.0 (GraphPad, San Diego, CA, USA).
Results
TNF-a induces MMP-9 release from brain pericytes
Gelatin zymographic analysis revealed a band at the posi-
tion approximately under the standard pro-MMP-9 band,
indicating that the supernatant of the pericytes had MMP-
9 activity (Figure 1A, arrowed band). A 24-h exposure to
TNF-a (1, 10 and 100 ng/mL) increased MMP-9 activities
in the supernatant of primary cultures of pericytes in a
concentration-dependent manner (31, 135 and 185% of
increase, respectively; Figure 1A). Western blot analysis
using an anti-MMP-9 antibody showed that in response to
TNF-a (10 and 100 ng/mL for 24 h) MMP-9 release from
pericytes increased in a concentration dependent manner
by 383 and 769% of vehicle, respectively (Figure 1B).
These increases in the MMP-9 protein levels were consis-
tent with the zymographic activities (Figure 1A). When
TNF-a was incubated at 95°C for 5 min, this denatured
TNF-a (100 ng/mL for 24 h) failed to induce MMP-9
release from pericytes (data not shown). TNF-a did not
induce significant changes in MMP-2 activities (1, 10 and
100 ng/mL: 171.8 ± 66.81, 160.2 ± 70.21 and 167.7 ±
66.46% of vehicle, respectively; n = 3-4) and MMP-2 levels
(Figure 1A, top panel and 1C, respectively). A 24-h expo-
sure to TNF-a (1, 10, and 100 ng/mL) showed no effect
on cell viability as determined by mitochondrial dehydro-
genase activity (WST-8) assay (99.6 ± 2.93, 109.8 ± 1.67
and 107.3 ± 1.70% of vehicle, respectively; n = 4). To
determine whether other inflammatory mediators induce
MMP-9 release from pericytes, we treated cells with inter-
leukin (IL)-1b,i n t e r f e r o n( I F N ) - g, IL-6 and LPS (1, 10, and
100 ng/mL of each substance) for 24 h. None of these
inflammatory mediators induced MMP-9 release from
pericytes (data not shown).
Pericytes are the major source of MMP-9 released from
cells constituting the BBB in response to TNF-a
We determined the TNF-a-induced MMP-9 release from
three cellular components of the BBB (BMECs, astrocytes
and pericytes) after treatment with 100 ng/mL TNF-a for
24 h. TNF-a significantly increased the release of MMP-9
from pericytes and astrocytes into the supernatant
(Figure 2A). Pericytes showed marked MMP-9 release
(33.6 ± 4.30 × 10
6 arbitrary unit/mg protein per 24 h),
whereas astrocytes and RBECs produced lower levels of
MMP-9 (13.4 ± 2.12 × 10
6 and 10.3 ± 2.16 × 10
6 arbitrary
unit/mg protein per 24 h, respectively; Figure 2A). This
TNF-a-induced MMP-9 release from pericytes was 3.3-
and 2.5-fold higher than from RBECs and astrocytes,
respectively. As shown in Figure 2B, TNF-a-induced
release of MMP-9 from the three cell types increased
with time. This increased response appeared within 12 h
in each culture. As TNF-a can bind to two structurally
distinct membrane receptors on target cells, TNFR1 (also
known as p55 and TNFRSF1A) and TNFR2 (also known
as p75 and TNFRSF1B), we examined their expression
levels in RBECs, astrocytes and pericytes (Figure 2C).
There were no significant differences in the expression
levels of TNFR1 among RBECs, astrocytes and pericytes
(Figure 2C). The expression level of TNFR2 in pericytes
was about 2.2-fold higher than in RBECs and astrocytes.
TNF-a induces MMP-9 release from pericytes via the p42/
p44 MAPK, JNK, and p38 MAPK pathways
We investigated whether MAPKs are involved in TNF-
a-induced MMP-9 release from pericytes. When peri-
cytes were pretreated with a MEK1/2 inhibitor (U0126),
a JNK inhibitor (SP600125) and a p38 MAPK inhibitor
(SB203580) for 15 min prior to a 24-h exposure to
TNF-a (100 ng/mL), TNF-a-induced MMP-9 release
was blocked by each inhibitor in a concentration-depen-
dent manner (Figure 3A, B and 3C, respectively). U0126
(10 μM), SP600125 (10 μM) and SB203580 (10 μM)
inhibited TNF-a-induced MMP-9 release by approxi-
mately 80, 75 and 35%, respectively. TNF-a (100 ng/mL
for 24 h) increased the phosphorylation levels of p42/
p44 MAPK, JNK and p38 MAPK in pericytes by 102, 75
and 110% of vehicle, respectively (Figure 3D).
TNF-a induces MMP-9 release from pericytes via the
phosphoinositide-3-kinase (PI3K)/Akt cascade
Pretreatment with the PI3K inhibitor, LY294002 (5 and 10
μM), significantly inhibited TNF-a-induced MMP-9 release
by approximately 30 and 80%, respectively (Figure 4A). To
test whether TNF-a stimulates phosphorylation of Akt, a
direct downstream target of PI3K, western blot analysis of
pericytes was performed using an anti-phospho-Akt anti-
body. Phospho-Akt levels were increased in TNF-a-treated
pericytes (100 ng/mL for 24 h), compared with vehicle-
treated pericytes (Figure 4B).
Up-regulation of MMP-9 is required for the induction of
pericyte migration
To evaluate the functional activity of the MMP-9
expression induced by TNF-a, we examined the cellular
migration of pericytes using a scratch wound healing
assay in vitro. Representative images show that TNF-a
(50 ng/mL) stimulated pericytes to migrate across the
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Page 4 of 12Figure 1 Release of MMP-9 and MMP-2 from brain pericytes after TNF-a treatment (1, 10 and 100 ng/mL) for 24 h.A ,R e p r e s e n t a t i v e
zymograms showing MMP-9 and MMP-2 activities in the culture media of pericytes (top panel). Densitometric analysis of MMP-9 (bottom panel)
and MMP-2 (data shown in the text) activities in the culture media of pericytes. B and C, Representative western blots (top panels) and
densitometric analysis (bottom panels) of protein levels of MMP-9 and MMP-2, respectively, in the culture media of pericytes. Band intensities
were quantified by scanning densitometry and the data are expressed as a percentage of control values (vehicle-treated pericytes). Each bar
indicates mean ± S.E.M. for three experiments. * P < 0.05, *** P < 0.001, significantly different from vehicle-treated group.
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Page 5 of 12Figure 2 TNF-a-induced MMP-9 release levels and the expression of TNFR1 and TNFR2 in the BBB cells RBECs, astrocytes and
pericytes. A, Representative western blots (top panel) and densitometric analysis (bottom panel) of MMP-9 levels in the culture media. Cells
were treated with TNF-a (100 ng/mL) for 24 h. Band intensities were quantified by scanning densitometry and the data are expressed as
arbitrary units/mg of protein. Each bar indicates mean ± S.E.M. for three experiments. * P < 0.05 and *** P < 0.001, significantly different from
vehicle-treated astrocytes and pericytes, respectively.
##P < 0.01, significantly different from TNF-a-treated astrocytes.
###P < 0.001, significantly
different from TNF-a-treated RBECs. B, Representative images showing the time-course of TNF-a-induced MMP-9 release from RBECs, astrocytes
and pericytes. Cells were treated with TNF-a (100 ng/mL) for 3 - 24 h. MMP-9 levels in the culture media were analyzed by western blot. Levels
in the culture media of TNF-a-treated pericytes were used as positive controls for levels in the media of TNF-a-treated RBECs and astrocytes. C,
Representative western blots (top panels) and densitometric analysis (bottom panel) of TNFR1 and TNFR2 expression in cell lysates of non-
treated RBECs, astrocytes and pericytes. Protein levels of TNFR1 and TNFR2 were normalized to b-actin and the data are expressed as a ratio
relative to b-actin. Each bar indicates mean ± S.E.M. for three experiments. * P < 0.05, significantly different from RBECs and astrocytes.
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Page 6 of 12wound edge into the scratched area 72 h after scratch-
ing (Figure 5A). The extent of TNF-a-induced pericyte
migration significantly increased to 189% of vehicle (Fig-
ure 5A). This TNF-a-accelerated migration of pericytes
was significantly inhibited and decreased to control
levels (vehicle) in the presence of anti-MMP-9 antibody
(Figure 5A). TNF-a failed to increase the extent of
migration of RBECs and astrocytes (Figure 5B and 5C).
Figure 3 Involvement of MAPKs (p42/p44 MAPK, JNK and p38 MAPK) in TNF-a-induced MMP-9 release from pericytes. A, B and C, Cells
were pretreated with U0126 (A), SP600125 (B) or SB203580 (C) for 15 min and then incubated with TNF-a (100 ng/mL) for 24 h. Representative
western blots (top panels) and densitometric analysis (bottom panels) of MMP-9 levels in the culture media. Band intensities were quantified by
scanning densitometry and the data are expressed as percentage of control values (vehicle-treated pericytes). Each bar indicates mean ± S.E.M.
for three or more experiments. *** P < 0.001, significantly different from vehicle-treated pericytes.
#P < 0.05, significantly different from TNF-a-
treated pericytes. D, Representative images of western blots showing total and phosphorylated p42/p44 MAPK, JNK and p38 MAPK in the cell
lysates of pericytes treated with TNF-a(100 ng/mL) for 24 h.
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In the present study, our major findings are: (1) at the
BBB, brain pericytes are the most sensitive machinery to
TNF-a for MMP-9 release; (2) pericytes release higher
levels of MMP-9 than BMECs or astrocytes; (3) TNF-a-
induced activation of MAPKs (p42/p44 MAPK, p38MAPK
and JNK) and PI3K/Akt are vital for increased expression
of MMP-9 in pericytes; (4) pericytal MMP-9 promotes cel-
lular migration.
Elevated levels of MMP-9 in the plasma and brain are
associated with BBB disruption, leading to an exacerbation
of neurodegenerative diseases [25]. MMP-9 is produced in
the cells constituting the BBB, including BMECs [26] and
astrocytes [27] under pathological conditions. Brain peri-
cytes also produce MMP-9 [28]; however, it has not been
clarified whether pericytes release MMP-9 in response to
various inflammatory stimuli. In this study, to examine the
ability of pericytes to release MMP-9 in response to var-
ious inflammatory stimuli, pericytes were treated with
TNF-a,I L - 1 b,I F N - g,I L - 6a n dL P S .T N F - a markedly
induced MMP-9 release from pericytes. MMP-2 release
was not stimulated by TNF-a in these cells, although
spontaneous release of MMP-2 was observed. This differ-
ent response of pericytes to TNF-a between MMP-2 and
MMP-9 release suggests that among MMPs, MMP-9 is a
potential factor in inducing neuroinflammation in the
brain. Interestingly, other inflammatory mediators, includ-
ing IL-1b,I F N - g, IL-6 and LPS; did not induce MMP-9
release from pericytes (data not shown). LPS, IL-1b and
TNF-a were inducers of MMP-9 in astrocytes and micro-
glia [29,30]. Here, we demonstrate that TNF-a is the cyto-
kine that induces MMP-9 release from pericytes.
Among the three cellular components of the BBB, peri-
cytes produced the highest levels of MMP-9 in response
to TNF-a.T h i sT N F - a-induced MMP-9 release
increased with time and did not reach a maximum peak
for MMP-9 release within 24 h. We evaluated the
amount of MMP-9 in the culture supernatants when
MMP-9 release was still increasing. Therefore, the possi-
bility that degradation of MMP-9 in culture supernatants
Figure 4 Involvement of the PI3K/Akt pathway in TNF-a-induced MMP-9 release from pericytes. A, Effect of PI3K inhibitor (LY294002) on
TNF-a-induced MMP-9 release from pericytes. Cells were pretreated with LY294002 for 15 min, and then incubated with TNF-a (100 ng/mL) for
24 h. MMP-9 levels in the culture media of pericytes were assayed by western blot. Band intensities were quantified by scanning densitometry
and the data are expressed as percentage of control values (vehicle-treated pericytes). Each bar indicates mean ± S.E.M. for three experiments.
*** P < 0.001, significantly different from vehicle-treated pericytes.
#P < 0.05, significantly different from TNF-a-treated pericytes. B, Representative
images showing western blots of total and phosphorylated Akt in the cell lysates of pericytes treated with TNF-a (100 ng/mL) for 24 h.
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Page 8 of 12Figure 5 Effect of TNF-a on migration of pericytes (A), RBECs (B) and astrocytes (C), which constitute the BBB. Pericytes were treated
with TNF-a (50 ng/mL) for 72 h in the presence of mouse IgG or anti-MMP-9 antibody. Astrocytes and RBECs were treated with TNF-a (50 ng/
mL) for 72 h. Representative phase-contrast images showing the fixed position in the wound area at 0 and 72 h after scratching (A: left panels; B
and C: top panels). The number of cells migrating into the initial wound area was counted at 72 h after scratching and the data are expressed
as mean ± S.E.M. for three experiments. (A: right panel; B and C: bottom panels). *P < 0.05, significantly different from vehicle-treated pericytes.
#P < 0.05, significantly different from TNF-a treated pericytes. Scale Bar = 100 μm.
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excluded. These findings suggest that in response to
TNF-a pericytes are the major machinery for MMP-9
release from cells constituting the BBB. TNF-a exerts its
biological functions by interacting with two members of
the TNF receptor superfamily, TNFR1 and TNFR2. We
found that TNFR2 expression was 2-fold higher in peri-
cytes compared with astrocytes and RBECs, although
TNFR1 expression was not statistically different among
these cells. These high levels of TNFR2 expression in
pericytes may largely contribute to the TNF-a-induced
MMP-9 release from pericytes.
Several studies have indicated that MAPKs (p42/p44
MAPK, p38 MAPK and JNK) and PI3K/Akt pathways are
involved in the regulation of MMP-9 expression in
endothelial cells [31], vascular smooth muscle cells [32],
astrocytes [29] and microglia [33]. TNF-a has been
reported to act as an important inflammatory mediator via
activation of MAPKs and PI3K/Akt cascades in various
cells [34,35]. However, the issue of how the activation of
signaling pathways in pericytes results in the induction of
MMP-9 is unclear. Here, we demonstrate that stimulation
of brain pericytes with TNF-a stimulates phosphorylation
of the p42/p44 MAPK, p38 MAPK, JNK and Akt. Inhibi-
tion of their activities by their pharmacological inhibitors
reduced TNF-a-induced MMP-9 release. These data pro-
vide evidence for involvement of the MAPKs and PI3K/
Akt pathways in mediating TNF-a-induced up-regulation
of MMP-9 release from pericytes. Binding of TNF-a to
TNFR1 and TNFR2 activates separate intracellular signal-
ing pathways [35]. We do not present direct evidence to
determine whether TNF-a activates MAPKs and PI3K/
Akt through TNFR1 and/or TNFR2 in pericytes. Whether
the TNF-a receptor subtypes have a role in the mediation
of TNF-a-induced MMP-9 release from pericytes is cur-
rently under investigation.
MMP-9 plays an essential role in the induction of cellu-
lar migration in several cell types [27,36,37]. In the present
study, TNF-a enhanced migration of pericytes, but failed
to facilitate migration of RBECs and astrocytes. These
findings suggest that the amount of MMP-9 induced by
TNF-a may be a determinant factor in the acceleration of
migration of these cells. Our cell viability assay excluded
the possibility that TNF-a stimulates the proliferation of
pericytes during the migration test. This TNF-a-induced
pericyte migration was suppressed by inhibition of MMP-
9 with an inhibitory antibody against MMP-9, indicating
that TNF-a stimulates pericytes to enhance migration
through MMP-9 release. The proteolytic activity of MMP-
9 to degrade extracellular matrices is required for cell
migration [38]. The MMP-9 hemopexin domain initiates
the intracellular signaling that induces cellular migration;
this activity is independent of its proteolytic activity
[36,38]. The antibody used in the present study is known
to neutralize the hemopexin domain of MMP-9 [39].
These findings raise the possibility that pericytes express
receptors for the hemopexin domain of MMP-9 including
LDL receptor-related protein 1 (LRP1). In fact, our wes-
tern blot analysis shows that LRP1 is expressed in peri-
cytes (data not shown). Therefore, TNF-a-accelerated
migration of pericytes may be attributed to these activities
of MMP-9.
Neuroinflammation has been implicated as a cause of
BBB disruption in CNS diseases such as stroke, bacterial
meningitis and neurodegenerative diseases [40]. The up-
regulation of various inflammatory cytokines under neu-
roinflammation conditions, especially TNF-a, is known to
be a trigger for MMP-9 expression in the brain [41-45].
Previously, we demonstrated that detachment of brain
pericytes from the basal lamina is related to disruption of
the BBB in LPS-injected mice [11]. Blood-born TNF-a is
transported across the BBB [46]. The findings that BMECs
secrete TNF-a into the parenchyma [47], and that glial
cells express TNF-a in the brain [48,49], are important to
understand the mechanism underlying the trigger for peri-
cyte migration. Considering these findings together with
our results, it is likely that in neuroinflammatory diseases
pericytes at the BBB are very sensitive to TNF-a, resulting
in release of MMP-9 through activation of MAPKs and
PI3K/Akt signaling pathways. Increased MMP-9 release
from pericytes may contribute to two possible pathways
that mediate BBB disruption: (1) degradation of extracellu-
lar matrices and tight junction proteins of BMECs; (2)
enhanced migration of pericytes from microvasculature,
appearing as “pericyte loss”. Therefore, we propose that
pericytes may be able to act as a sensor for neuroinflam-
matory signals produced by BMECs and brain parenchy-
mal cells (e.g. glial cells), and subsequently release MMP-9
to initiate migration of pericytes. This series of events is
an important inflammatory response at the BBB. Further
investigations are required to elucidate the pericytes’ role
during and/or after migration.
Conclusions
In this study, we demonstrate in vitro that pericytes are
the major source of MMP-9 release induced by TNF-a at
the BBB and that pericyte-derived MMP-9 enhances
their migration. Up-regulation of MMP-9 in the cerebral
microvasculature probably causes BBB disruption
through degradation of tight junctions and extracellular
matrices, and subsequent pericyte loss from microvascu-
lature. Therefore, pericytes and pericytal MMP-9 could
be attractive therapeutic targets for ameliorating BBB
dysfunction in neuroinflammatory diseases.
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